© 1991 by Oxford University Press
Journal of the National Cancer Institute, Vol. 83, No. 20, 1460-1470,
October 16, 1991
© 1991 Oxford University Press
Influence of Doxorubicin Dose Intensity on Response and Outcome for Patients With Osteogenic Sarcoma and Ewing's Sarcoma
Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute Bethesda, Md.
Pediatric Branch, Division of Cancer Treatment, National Cancer Institute.
*Correrspondence to: Malcolm A. Smith, M.D., Cancer Therapy Evaluation Program, National Institutes of Health, Executive Plaza North, Rm. 741, Bethesda, MD 20892.
The goal of this study was to use dose-intensity analyses of published Ewing's sarcoma and osteogenic sarcoma trials to determine which agents were most closely associated with a favorable response. The percentage of patients with more than 90% tumor necrosis following neoadjuvant chemotherapy was the end point for analysis of osteogenic sarcoma trials, and disease-free survival and percentage of patients with distant-only relapse were the end points for analysis of Ewing's sarcoma trials. The data were analyzed using logistic regression analysis to circumvent the distortion of univariate analysis resulting from the correlation between doxorubicin dose intensity and the dose intensity of other agents. Our analysis suggests that doxorubicin dose intensity is an important determinant of favorable outcome for both Ewing's sarcoma and osteogenic sarcoma and that the dose intensities of other agents do not contribute as significantly to outcome as does doxorubicin dose intensity. Increasing dactinomycin dose intensity was associated with a poorer outcome in treatment of osteogenic sarcoma and Ewing's sarcoma, most likely resulting from regimens with a higher dactinomycin dose intensity having a lower doxorubicin dose intensity. While our analysis of osteogenic sarcoma trials is consistent with significant activity for cisplatin and high-dose methotrexate (and likely ifosfamide), a rank ordering of the efficacy of these agents when given with doxorubicin in multiagent regimens is not possible. Our analysis illustrates the importance of analyzing the contributions of individual agents to combination chemotherapy regimens. In the design of future clinical trials for osteogenic sarcoma and Ewing's sarcoma, careful attention should be given to optimizing doxorubicin dose intensity in regimens to be tested. [J Natl Cancer Inst 83: 1460–1470, 1991]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Granowetter, R. Womer, M. Devidas, M. Krailo, C. Wang, M. Bernstein, N. Marina, P. Leavey, M. Gebhardt, J. Healey, et al. Dose-Intensified Compared With Standard Chemotherapy for Nonmetastatic Ewing Sarcoma Family of Tumors: A Children's Oncology Group Study J. Clin. Oncol., May 20, 2009; 27(15): 2536 - 2541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Imran, F. Enders, M. Krailo, F. Sim, S. Okuno, D. Hawkins, J. Neglia, R. L. Randall, R. Womer, L. Mascarenhas, et al. Effect of Time to Resumption of Chemotherapy After Definitive Surgery on Prognosis for Non-Metastatic Osteosarcoma J. Bone Joint Surg. Am., March 1, 2009; 91(3): 604 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Skubitz and D. R. D'Adamo Sarcoma Mayo Clin. Proc., November 1, 2007; 82(11): 1409 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Miller, L. Emerson, F. Clayton, B. G. Bentz, R. E. Data, K. L. Salzman, L. M. Smith, and M. K. Yu Extraosseous Ewing's Sarcoma J. Clin. Oncol., October 20, 2007; 25(30): 4845 - 4848. [Full Text] [PDF]
|
|
|
|
|
|
C. L. Schwartz, R. Gorlick, L. Teot, M. Krailo, Z. Chen, A. Goorin, H. E. Grier, M. L. Bernstein, and P. Meyers Multiple Drug Resistance in Osteogenic Sarcoma: INT0133 From the Children's Oncology Group J. Clin. Oncol., May 20, 2007; 25(15): 2057 - 2062. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. J. Lewis, M. A. Nooij, J. Whelan, M. R. Sydes, R. Grimer, P. C. W. Hogendoorn, M. A. Memon, S. Weeden, B. M. Uscinska, M. van Glabbeke, et al. Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma Intergroup J Natl Cancer Inst, January 17, 2007; 99(2): 112 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Marina, M. Gebhardt, L. Teot, and R. Gorlick Biology and Therapeutic Advances for Pediatric Osteosarcoma Oncologist, July 1, 2004; 9(4): 422 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.J. Strauss, A. McTiernan, D. Driver, M. Hall-Craggs, A. Sandison, A.M. Cassoni, A. Kilby, M. Michelagnoli, J. Pringle, J. Cobb, et al. Single Center Experience of a New Intensive Induction Therapy for Ewing's Family of Tumors: Feasibility, Toxicity, and Stem Cell Mobilization Properties J. Clin. Oncol., August 1, 2003; 21(15): 2974 - 2981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hirschfeld, P. T.C. Ho, M. Smith, and R. Pazdur Regulatory Approvals of Pediatric Oncology Drugs: Previous Experience and New Initiatives J. Clin. Oncol., March 15, 2003; 21(6): 1066 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Fagioli, M. Aglietta, A. Tienghi, S. Ferrari, A. Brach del Prever, E. Vassallo, A. Palmero, E. Biasin, G. Bacci, P. Picci, et al. High-Dose Chemotherapy in the Treatment of Relapsed Osteosarcoma: An Italian Sarcoma Group Study J. Clin. Oncol., April 15, 2002; 20(8): 2150 - 2156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Bielack, B. Kempf-Bielack, G. Delling, G. U. Exner, S. Flege, K. Helmke, R. Kotz, M. Salzer-Kuntschik, M. Werner, W. Winkelmann, et al. Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols J. Clin. Oncol., February 1, 2002; 20(3): 776 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Marina, D. Cochrane, E. Harney, K. Zomorodi, S. Blaney, N. Winick, M. Bernstein, and M. P. Link Dose Escalation and Pharmacokinetics of Pegylated Liposomal Doxorubicin (Doxil) in Children with Solid Tumors: A Pediatric Oncology Group Study Clin. Cancer Res., February 1, 2002; 8(2): 413 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. J. Lewis, S. Weeden, D. Machin, D. Stark, and A. W. Craft Received Dose and Dose-Intensity of Chemotherapy and Outcome in Nonmetastatic Extremity Osteosarcoma J. Clin. Oncol., December 15, 2000; 18(24): 4028 - 4037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Smith, J. Abrams, E. L. Trimble, and R. S. Ungerleider Dose Intensity of Chemotherapy for Childhood Cancers Oncologist, October 1, 1996; 1(5): 293 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Lipshultz, S. R. Lipsitz, S. M. Mone, A. M. Goorin, S. E. Sallan, S. P. Sanders, E. J. Orav, R. D. Gelber, and S. D. Colan Female Sex and Higher Drug Dose as Risk Factors for Late Cardiotoxic Effects of Doxorubicin Therapy for Childhood Cancer N. Engl. J. Med., June 29, 1995; 332(26): 1738 - 1744. [Abstract] [Full Text] [PDF]
|
|